162 related articles for article (PubMed ID: 31032226)
1. A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers.
Weinberger V; Bednarikova M; Hausnerova J; Ovesna P; Vinklerova P; Minar L; Felsinger M; Jandakova E; Cihalova M; Zikan M
Front Oncol; 2019; 9():265. PubMed ID: 31032226
[No Abstract] [Full Text] [Related]
2. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.
Karnezis AN; Leung S; Magrill J; McConechy MK; Yang W; Chow C; Kobel M; Lee CH; Huntsman DG; Talhouk A; Kommoss F; Gilks CB; McAlpine JN
J Pathol Clin Res; 2017 Oct; 3(4):279-293. PubMed ID: 29085668
[TBL] [Abstract][Full Text] [Related]
4. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
6. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
Pasanen A; Loukovaara M; Tuomi T; Bützow R
Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
[TBL] [Abstract][Full Text] [Related]
8. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
9. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
[TBL] [Abstract][Full Text] [Related]
10. Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma.
Salama A; Arafa M; ElZahaf E; Shebl AM; Awad AAE; Ashamallah SA; Hemida R; Gamal A; Foda AA; Zalata K; Abdel-Hady EM
J Pathol Transl Med; 2019 May; 53(3):164-172. PubMed ID: 30813708
[TBL] [Abstract][Full Text] [Related]
11. L1CAM: amending the "low-risk" category in endometrial carcinoma.
Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
14. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
Zeimet AG; Reimer D; Huszar M; Winterhoff B; Puistola U; Azim SA; Müller-Holzner E; Ben-Arie A; van Kempen LC; Petru E; Jahn S; Geels YP; Massuger LF; Amant F; Polterauer S; Lappi-Blanco E; Bulten J; Meuter A; Tanouye S; Oppelt P; Stroh-Weigert M; Reinthaller A; Mariani A; Hackl W; Netzer M; Schirmer U; Vergote I; Altevogt P; Marth C; Fogel M
J Natl Cancer Inst; 2013 Aug; 105(15):1142-50. PubMed ID: 23781004
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of intraoperative gross examination of myometrial invasion in stage I-II endometrial cancer.
Sethasathien P; Charoenkwan K; Siriaunkgul S
Asian Pac J Cancer Prev; 2014; 15(17):7061-4. PubMed ID: 25227791
[TBL] [Abstract][Full Text] [Related]
16. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.
Reijnen C; Gogou E; Visser NCM; Engerud H; Ramjith J; van der Putten LJM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Reques A; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AAM; Matias-Guiu X; Amant F; ; Massuger LFAG; Snijders MPLM; Küsters-Vandevelde HVN; Lucas PJF; Pijnenborg JMA
PLoS Med; 2020 May; 17(5):e1003111. PubMed ID: 32413043
[TBL] [Abstract][Full Text] [Related]
17. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
18. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
19. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer.
Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J
Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990
[TBL] [Abstract][Full Text] [Related]
20. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study.
Visser NC; Bulten J; van der Wurff AA; Boss EA; Bronkhorst CM; Feijen HW; Haartsen JE; van Herk HA; de Kievit IM; Klinkhamer PJ; Pijlman BM; Snijders MP; Vandenput I; Vos MC; de Wit PE; van de Poll-Franse LV; Massuger LF; Pijnenborg JM
BMC Cancer; 2015 Jun; 15():487. PubMed ID: 26123742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
